IMMPACT

What IMMPACT does

IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials) is a multidisciplinary research consortium founded in November 2002 that develops consensus reviews and recommendations for improving the design, execution, and interpretation of clinical trials of treatments for pain in adults and children. The initiative has convened 25 consensus meetings to date, drawing invited participants from academia, regulatory agencies (U.S. FDA, EMA), the NIH, the U.S. Veterans Administration, consumer advocacy groups, and industry, across disciplines including anesthesiology, clinical pharmacology, neurology, oncology, psychology, rheumatology, nursing, and law. Its core outputs are published consensus recommendations and systematic reviews, which are described as widely cited and influential in guiding the design of pain clinical trials, other clinical research, and a national survey, along with the SF-MPQ-2 (Short-Form McGill Pain Questionnaire-2) outcome instrument, whose licensing is managed by Mapi Research Trust.

Since September 15, 2010, IMMPACT's meetings, publications, and activities have been conducted under the auspices of ACTTION (Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks), a public-private partnership with the U.S. FDA. Leadership is provided by Robert H. Dworkin, PhD (ACTTION Director, University of Rochester) and Dennis C. Turk, PhD (ACTTION Associate Director, University of Washington). IMMPACT is not a traditional corporation: it has no commercial pricing model, no disclosed revenue, no funding rounds, and no equity ownership structure in the source data. It operates as a research initiative embedded within two university medical centers (Rochester, NY and Seattle, WA) and disseminates its outputs through peer-reviewed publications, its website (immpact.org), and consensus meetings rather than commercial channels.

Name

IMMPACT

Legal name

IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials)

Website

https://immpact.org

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

IMMPACT is a multidisciplinary research consortium, founded in 2002 and operating under ACTTION/FDA, that develops widely cited consensus recommendations and outcome measures (including SF-MPQ-2) to improve clinical trial design for pain treatments in adults and children.

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Technology or R&D

Revenue model

1. Instrument Licensing: SF-MPQ-2 licensing is managed through Mapi Research Trust, which handles permissions and translations for the instrument.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

IMMPACT is a multidisciplinary research consortium that develops consensus reviews and recommendations for improving the design, execution, and interpretation of clinical trials of treatments for pain. Since 2002, the initiative has convened 25 consensus meetings covering acute and chronic pain in adults and children, involving participants from academia, regulatory agencies (FDA, EMA), NIH, VA, industry, and patient advocacy groups. The initiative also developed the SF-MPQ-2 standardized pain assessment instrument, licensed through Mapi Research Trust.

Product overview

IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials) is a multidisciplinary research consortium that operates as a single unified initiative rather than a platform-plus-modules architecture. The organization develops consensus recommendations through 25 held meetings to improve clinical trial design for pain treatments. Key offerings include the consensus recommendations and reviews themselves, the SF-MPQ-2 pain assessment questionnaire, and the ACTTION public-private partnership with FDA that oversees these activities.

Differentiator

Problem solved

Functional benefit

Products and services

• IMMPACT Consensus Recommendations Consensus reviews and recommendations developed through multidisciplinary meetings to improve the design, execution, and interpretation of clinical trials of treatments for pain in adults and children. Disseminated via peer-reviewed publications and the IMMPACT website, and used by academic researchers, regulatory agencies (FDA, EMA), NIH, VA, industry, and patient advocacy groups.
• SF-MPQ-2 (Short-Form McGill Pain Questionnaire 2) Standardized pain assessment questionnaire developed through IMMPACT collaborations for measuring pain intensity and quality in clinical trials of pain treatments. Permissions, licensing, and translations are managed through Mapi Research Trust in Lyon, France.

Quantifiable outcome

• IMMPACT recommendations have guided the design of clinical trials, other types of clinical research, and a national survey

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Seven partnerships are on record, tiered core and minor.

• ACTTION (Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks)coreStrategic or Co-development Partner · 15 September 2010Effective September 15, 2010, IMMPACT consensus meetings, publications, and other activities are conducted under the auspices of ACTTION, a public-private partnership with the United States Food and Drug Administration. ACTTION coordinates the ongoing consensus meetings and research initiatives.
• Mapi Research TrustcoreStrategic or Co-development PartnerMapi Research Trust manages permissions and licensing for the SF-MPQ-2 (Short-Form McGill Pain Questionnaire-2) and its translations. Located in Lyon, France.
• United States Food and Drug Administration (FDA)coreStrategic or Co-development PartnerFDA is a key partner through the ACTTION public-private partnership. FDA representatives participate in IMMPACT consensus meetings and help guide the development of clinical trial methodology recommendations.
• European Medicines Agency (EMA)coreStrategic or Co-development PartnerEMA participates in IMMPACT consensus meetings, bringing European regulatory perspective to pain clinical trial methodology development.
• US National Institutes of Health (NIH)coreStrategic or Co-development PartnerNIH participates in IMMPACT meetings through various institutes including NIDA, NIAMS, and NINDS. NIH representatives contribute to consensus recommendations on pain clinical trial design.
• US Veterans Administration (VA)minorStrategic or Co-development PartnerVA representatives participate in IMMPACT consensus meetings, contributing perspective on pain treatment research for veterans.
• International Academic InstitutionscoreStrategic or Co-development PartnerIMMPACT has drawn participants from academic institutions across multiple countries including Australia, Austria, Canada, Denmark, France, Germany, Portugal, the United Kingdom, and the United States.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• NIH Pain Consortium: U.S. National Institutes of Health-coordinated body that enhances pain research collaboration across institutes; comparable in convening role and regulatory influence on U.S. pain research priorities.
• Society for Clinical Trials: Professional organization advancing the design, conduct, and analysis of clinical trials; methodological peer whose work intersects with IMMPACT's clinical-trial-design consensus recommendations.
• International Association for the Study of Pain (IASP): The leading global professional society for pain research and treatment; IASP convenes the broader pain research community that IMMPACT draws from and complements with trial-methodology-specific consensus work.

Direct peers

• SPIRIT Initiative: Produces international consensus guidelines for clinical trial protocols; comparable methodology-consensus model applied to trial design, similar to IMMPACT's role in pain trials.
• COMET Initiative (Core Outcome Measures in Effectiveness Trials): Consortium focused on developing and applying core outcome sets across clinical trials; directly comparable in mission and methodology to IMMPACT's outcome-measure consensus work.
• Critical Path Institute (C-Path): Independent nonprofit that develops regulatory-grade methodologies, data standards, and drug development tools through public-private partnerships with FDA and EMA — a direct analogue to IMMPACT's consensus model in adjacent therapeutic areas.
• CONSORT Group: International initiative that produces consensus guidelines for reporting randomized controlled trials; methodologically analogous to IMMPACT's trial-methodology consensus approach.
• Clinical Trials Transformation Initiative (CTTI): Public-private partnership co-founded by FDA and Duke that develops evidence-based recommendations to improve clinical trial design and conduct — directly comparable to IMMPACT's regulatory consensus-building mission.
• ACTTION (Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks): IMMPACT's parent partnership organization and host of its activities since 2010; a public-private partnership with the FDA focused on clinical trial methodology for analgesics and addiction treatments — the most directly comparable entity.

Emerging players

• COSMIN: Initiative developing consensus-based standards for evaluating the measurement properties of health outcome instruments; overlaps with IMMPACT's work in validating pain assessment tools like SF-MPQ-2.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMMPACT